Protalix BioTherapeutics Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Protalix BioTherapeutics will hold its 2024 Annual Meeting on June 27, 2024, to vote on directors, executive compensation, stock incentive plan amendments, and auditor ratification.</b>

AI Summary

Protalix BioTherapeutics, Inc. (PLX) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. The 2024 Annual Meeting of Stockholders for Protalix BioTherapeutics, Inc. will be held on June 27, 2024, at 11:30 AM EDT. The meeting will take place at the Lotte New York Palace Hotel, Garrison Room, 455 Madison Avenue, New York, NY 10022. Key agenda items include the election of directors and an advisory vote on executive compensation. Stockholders will vote on amendments to the 2006 Stock Incentive Plan to increase available shares from 12,475,171 to 17,475,171. The appointment of the independent registered public accounting firm for the fiscal year ending December 31, 2024, will be ratified.

Why It Matters

For investors and stakeholders tracking Protalix BioTherapeutics, Inc., this filing contains several important signals. Shareholders have the opportunity to influence the company's governance by electing directors and providing advisory input on executive compensation. The proposed increase in the stock incentive plan shares is crucial for future employee retention and equity-based compensation strategies.

Risk Assessment

Risk Level: low — Protalix BioTherapeutics, Inc. shows low risk based on this filing. This filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would alter the company's risk profile.

Analyst Insight

Stockholders should carefully review the proposals regarding director elections and executive compensation, as well as the proposed amendments to the stock incentive plan, before voting.

Key Numbers

• 17,475,171 — Shares (Proposed total shares available under the 2006 Stock Incentive Plan after amendment)
• 12,475,171 — Shares (Current shares available under the 2006 Stock Incentive Plan)
• 2024 — Fiscal Year (Fiscal year for which the independent registered public accounting firm is being ratified)

Key Players & Entities

• Protalix BioTherapeutics, Inc. (company) — Registrant and company holding the annual meeting
• June 27, 2024 (date) — Date of the 2024 Annual Meeting of Stockholders
• Lotte New York Palace Hotel (company) — Location of the annual meeting
• Eyal Rubin (person) — Signed the letter to stockholders

FAQ

Risk Factors

• Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC rules and regulations regarding proxy solicitations and annual meetings.

Industry Context

Protalix BioTherapeutics operates in the biotechnology sector, focusing on the development and commercialization of protein-based therapeutics.

Regulatory Implications

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies.

What Investors Should Do

1. Review the proposals for director elections and advisory vote on executive compensation.
2. Analyze the proposed amendments to the 2006 Stock Incentive Plan, particularly the increase in available shares.
3. Vote on the ratification of the independent registered public accounting firm for fiscal year 2024.

Key Dates

• 2024-06-27: 2024 Annual Meeting of Stockholders — Key date for voting on corporate matters including director elections and stock plan amendments.

Glossary

DEF 14A

Definitive Proxy Statement (This filing type indicates the company is providing definitive proxy materials to shareholders for voting.)

Stock Incentive Plan

A plan that grants employees stock options or other equity-based awards. (Amendments to this plan, including share increases, are a key voting item for shareholders.)

Year-Over-Year Comparison

This is a Definitive Proxy Statement (DEF 14A) filing, which is a standard annual disclosure, not a change from a previous filing type.

Key Financial Figures

• $0.001 — f record of our common stock, par value $0.001 per share, on April 29, 2024 (the "Reco
• $10,000 — ill pay Alliance Advisors a base fee of $10,000, plus reasonable out-of-pocket expenses
• $100,000 — Alliance Advisors will be approximately $100,000. Could Other Matters Be Decided At Th

Filing Documents

• tm2412127-1_def14a.htm (DEF 14A) — 741KB
• lg_protalix-4c.jpg (GRAPHIC) — 10KB
• px_24protalixproxy01-bw.jpg (GRAPHIC) — 209KB
• px_24protalixproxy02-bwlr.jpg (GRAPHIC) — 326KB
• sg_eyalrubin-bw.jpg (GRAPHIC) — 5KB
• 0001104659-24-054084.txt (&nbsp;) — 1444KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth information, as of April 29, 2024, regarding beneficial ownership of our common stock: each person who is known by us to own beneficially more than 5% of our common stock; each director; each of our executive officers; and all of our directors and executive officers collectively. Unless otherwise noted, we believe that all persons named in the table have sole voting and investment power with respect to all shares of our common stock beneficially owned by each of them. For purposes of this table, a person is deemed to be the beneficial owner of securities that can be acquired by such person within 60 days from April 29, 2024 upon exercise of options, warrants and convertible securities. Each beneficial owner's percentage ownership is determined by assuming that options, warrants and convertible securities that are held by such person (but not those held by any other person) and that are exercisable or convertible within 60 days from such date have been exercised. The information set forth below is based upon information obtained from the beneficial owners, upon information in our possession regarding their respective holdings and upon information filed by the holders with the SEC. The percentages of beneficial ownership are based on 73,316,084 shares of our common stock outstanding as of April 29, 2024. The address for all directors and officers is c/o Protalix BioTherapeutics, Inc., 2 Snunit Street, Science Park, P.O. Box 455, Carmiel 2161401, Israel. Name and Address of Beneficial Owner Amount and Nature of Beneficial Ownership Percentage of Class (%) Board of Directors and Executive Officers Eliot Richard Forster, Ph.D. (1) 21,428 * Dror Bashan (2) 2,770,059 3.8 Amos Bar Shalev (3) 72,322 * Shmuel "Muli" Ben Zvi, Ph.D. (4) 32,154 * Pol F. Boudes, M.D. (5) 72,194 * Gwen A. Melincoff (6) 72,154 * Aharon Schwart

View Full Filing

View this DEF 14A filing on SEC EDGAR